series-c-plus
Stage
1
Investors
About
Somagenetix develops ex vivo gene therapy solutions targeting inherited phagocytosis disorders.
Explore Somagenetix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.